基于免疫检查点调节的 CAR-T 细胞疗法在血液恶性肿瘤治疗中的应用。

IF 3.2 4区医学 Q3 CELL & TISSUE ENGINEERING

Cell Transplantation Pub Date : 2024-01-01 DOI:10.1177/09636897241293964

Manqi Su, Zhanna Zhang, Panruo Jiang, Xiaoxia Wang, Xiangmin Tong, Gongqiang Wu

{"title":"基于免疫检查点调节的 CAR-T 细胞疗法在血液恶性肿瘤治疗中的应用。","authors":"Manqi Su, Zhanna Zhang, Panruo Jiang, Xiaoxia Wang, Xiangmin Tong, Gongqiang Wu","doi":"10.1177/09636897241293964","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that has shown significant success in treating certain hematologic malignancies. However, there are still challenges and limitations associated with this therapy, and not all cancer patients benefit from this therapy alone. Therefore, modifying CAR-T-cell therapy based on immune checkpoints, and its combination with immune checkpoint inhibitors (ICIs), shows promise as a potentially more effective strategy for treating hematologic malignancies. This article outlines the progress of preclinical and clinical trials of CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"33 ","pages":"9636897241293964"},"PeriodicalIF":3.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.\",\"authors\":\"Manqi Su, Zhanna Zhang, Panruo Jiang, Xiaoxia Wang, Xiangmin Tong, Gongqiang Wu\",\"doi\":\"10.1177/09636897241293964\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that has shown significant success in treating certain hematologic malignancies. However, there are still challenges and limitations associated with this therapy, and not all cancer patients benefit from this therapy alone. Therefore, modifying CAR-T-cell therapy based on immune checkpoints, and its combination with immune checkpoint inhibitors (ICIs), shows promise as a potentially more effective strategy for treating hematologic malignancies. This article outlines the progress of preclinical and clinical trials of CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies.\",\"PeriodicalId\":9721,\"journal\":{\"name\":\"Cell Transplantation\",\"volume\":\"33 \",\"pages\":\"9636897241293964\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09636897241293964\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09636897241293964","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体（CAR）T 细胞疗法是一种革命性的免疫疗法，在治疗某些血液系统恶性肿瘤方面取得了巨大成功。然而，这种疗法仍存在挑战和局限性，并非所有癌症患者都能从这种疗法中获益。因此，基于免疫检查点的 CAR-T 细胞疗法及其与免疫检查点抑制剂（ICIs）的联合疗法有望成为治疗血液系统恶性肿瘤的一种更有效的潜在策略。本文概述了基于免疫检查点调节的 CAR-T 细胞疗法治疗血液恶性肿瘤的临床前和临床试验进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that has shown significant success in treating certain hematologic malignancies. However, there are still challenges and limitations associated with this therapy, and not all cancer patients benefit from this therapy alone. Therefore, modifying CAR-T-cell therapy based on immune checkpoints, and its combination with immune checkpoint inhibitors (ICIs), shows promise as a potentially more effective strategy for treating hematologic malignancies. This article outlines the progress of preclinical and clinical trials of CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell Transplantation 生物-细胞与组织工程

CiteScore

6.00

自引率

3.00%

发文量

审稿时长

6 months

期刊介绍： Cell Transplantation, The Regenerative Medicine Journal is an open access, peer reviewed journal that is published 12 times annually. Cell Transplantation is a multi-disciplinary forum for publication of articles on cell transplantation and its applications to human diseases. Articles focus on a myriad of topics including the physiological, medical, pre-clinical, tissue engineering, stem cell, and device-oriented aspects of the nervous, endocrine, cardiovascular, and endothelial systems, as well as genetically engineered cells. Cell Transplantation also reports on relevant technological advances, clinical studies, and regulatory considerations related to the implantation of cells into the body in order to provide complete coverage of the field.